718results about "Tissue culture" patented technology

A method for transporting a biological sample at hypothermic temperatures. The container can be cooled using phase change material and pump fluid through the sample. The fluid can pump through the system at a rate independent of the parameters of the biological sample. A valve can control the rate of flow of the fluid into the biological sample.

This disclosure provides nanoparticle compositions, and use thereof for isolating and measuring proteins, protein degrader action, and cells. The disclosed nanoparticles can be identified by barcodes that reveal the identity of and post translational modifications to the bound protein using image processing techniques described herein.

The invention relates to a hybridoma cell strain capable of secreting a mefos monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. According to the invention, the hybridoma cell strain capable of secreting the fenofos monoclonal antibody is obtained through screening, the fenofos monoclonal antibody has high specificity and high sensitivity to the fenofos, IC50 to the fenofos is 0.231 ng / mL, and the fenofos monoclonal antibody has no cross reaction to structural analogues of the fenofos, such as triazophos, diazinon, phorate, acetyl phorate, methamidophos and the like; therefore, low-concentration isoprophos can be accurately detected.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of bovine coronavirus S2 protein, an epitope of the monoclonal antibody and application of the epitope. The invention provides a hybridoma cell strain (preservation number: CCTCC (China Center For Type Culture Collection) NO: C202510). The cell strain can secrete a monoclonal antibody which is targeted and combined with bovine coronavirus S2 protein; the amino acid sequence of the epitope identified by the monoclonal antibody is shown as SEQ ID NO: 1. Experiments prove that the monoclonal antibody has neutralizing activity, and the targeting epitope of the monoclonal antibody is a key neutralizing epitope. The invention provides a new strategy and tool for antibody drug and vaccine research and development as well as diagnosis and detection of the bovine coronavirus.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The present disclosure includes hyperbranched polyether polyols, such as hyperbranched poly(3-(oxiran-2-ylmethoxy) propane-1,2-diol) (HPOD), methods for their preparation and uses thereof, for example, as a cryoprotectant, lyoprotectant or stabilizer.

The invention relates to a medetomidine hapten, a monoclonal antibody, a hybridoma cell strain and application thereof, and belongs to the technical field of immunodetection. A medetomidine complete antigen is obtained by synthesizing a medetomidine hapten, a mouse is used as an immune animal to prepare a hybridoma cell strain secreting a medetomidine monoclonal antibody, the hybridoma cell strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46518. The medetomidine monoclonal antibody secreted by the hybridoma cell strain has better detection sensitivity and detection specificity to medetomidine, the IC50 value is 10.42 ng / mL, and the cross reaction rate to various medetomidine analogues is lt; the method can be applied to preparation of medetomidine detection products, and provides a reliable tool for immunodetection of medetomidine.

The invention provides an anti-duck adenovirus 3 type monoclonal antibody, a hybridoma cell strain and application thereof, the anti-duck adenovirus 3 type monoclonal antibody is secreted by a hybridoma cell strain 2F12, the classification name of the hybridoma cell strain 2F12 is Hybridoma cell line 2F12, the hybridoma cell strain 2F12 is preserved in China Center for Type Culture Collection on November 13, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CGMCC NO. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The blocking ELISA kit for detecting the duck adenovirus 3 antibody, which is prepared by utilizing the monoclonal antibody, is strong in specificity, high in sensitivity and good in repeatability, and has a very good application prospect in the aspects of epidemiological investigation of the duck adenovirus 3, vaccine immune efficacy evaluation and diagnosis of the duck adenovirus 3 disease.

The invention relates to a beta-CTx binding antibody or an antigen binding fragment thereof, the beta-CTx binding antibody comprises a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region contain HCDR and LCDR sequences; the invention also relates to corresponding isolated nucleic acid molecules, expression vectors and host cells. In addition, the invention also relates to a kit and a method for diagnosing osteoporosis in a subject.

The invention discloses a high-affinity monoclonal antibody for recognizing group B streptococcus SIP (Session Initiation Protocol) protein or an antigen binding fragment thereof. The amino acid sequence of a heavy chain variable region of the antibody is as shown in SEQ ID NO.1, and the amino acid sequence of a light chain variable region of the antibody is as shown in SEQ ID NO.5. The lowest detection limit of the group B streptococcus SIP protein double-antibody sandwich enzyme-linked immunosorbent assay established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on the SIP protein is 0.32 ng / mL. The lowest detection limit of a group B streptococcus SIP protein double-antibody sandwich fluorescence immunochromatography assay method established by taking the monoclonal antibody or the antigen binding fragment thereof as a capture antibody on SIP protein is 0.08 ng / mL, and the lowest detection limit on GBS bacterial liquid reaches 1 * 10 < 3 > CFU / mL, which is obviously higher than the lowest detection limit of the existing detection reagent and literature report; the method can be used for qualitative and quantitative detection of the group B streptococcus SIP protein.

The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody as well as a hybridoma cell strain and application thereof, and belongs to the technical field of immune globulin. The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody and also provides a hybridoma cell strain OTI10F11, the hybridoma cell strain OTI10F11 is preserved in the China General Microbiological Culture Collection Center on April 26, 2025, and the preservation number of the hybridoma cell strain OTI10F11 is No.46356. The invention further provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody. The hybridoma cell strain OTI10F11 provided by the invention can stably secrete an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody, and can be specifically combined with H < + > / K < + > ATPase beta protein, so that the specificity, accuracy and reliability of immunodetection are remarkably improved, and the hybridoma cell strain OTI10F11 can be suitable for marking H < + > / K < + > ATPase beta protein in tissue cells.

The application discloses a hybridoma cell strain secreting an anti-tilapia interleukin-2 monoclonal antibody and an application thereof, and the hybridoma cell strain 1C11F5 is preserved in the China Center for Type Culture Collection (CCTCC) on March 9, 2024, and the preservation number is CCTCC NO: C202470. The application can specifically identify the tilapia IL-2 protein and the lymphocyte group secreting IL-2, is helpful for further exploration of T cell activation and proliferation, and provides an important immunological tool for adaptive immune mechanism research of hard fish (such as tilapia and the like).

The invention discloses long-acting high-dynamic hydrazone bond hydrogel as well as a preparation method and application thereof, and particularly relates to the technical field of biomedical materials. The preparation method comprises the following steps: taking 1-adamantane acetic acid and adipic dihydrazide modified sodium hyaluronate and benzaldehyde-terminated eight-arm polyethylene glycol as carrier raw materials; the hydrazone bond hydrogel with relatively high stability is prepared through a coupling reaction of an aldehyde group of benzaldehyde-terminated eight-arm polyethylene glycol and a hydrazide group of 1-adamantane acetic acid and adipic dihydrazide modified sodium hyaluronate. The beta-cyclodextrin modified m-phenylenediamine catalyst is dynamically combined into the carrier through reversible host-guest complexation between beta-cyclodextrin and 1-adamantane acetic acid, so that the long-acting high-dynamic hydrazone bond hydrogel is obtained, and the requirement of three-dimensional culture of stem cells on mechanical properties can be met; and network dynamics can be maintained for a long time, so that stem cell spreading is supported, mechanical signal transduction is activated, osteogenesis-related gene expression is promoted, and stem cell osteogenesis differentiation capability is enhanced.

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.

The invention relates to the field of cells, in particular to a cell culture method which comprises the following steps: S1, taking out a cryopreservation tube from liquid nitrogen; s2, quickly putting the mixture into a water bath, and shaking the mixture from time to time to quickly melt the mixture; s3, wiping and disinfecting a cryopreservation tube with alcohol, opening a cover, injecting the cell suspension into a centrifugal tube by using a suction tube, dropwise adding a culture solution, and carrying out low-speed centrifugation; s4, pouring out the supernate, and adding a culture solution to suspend the cells; s5, sucking the cells into a culture dish filled with a culture solution, and slightly shaking all around, so that the cells in the culture dish are uniformly distributed; s6, placing the culture dish in an incubator at 37 DEG C for culturing; and S7, during culture, replacing a culture solution in the culture dish through a solution replacement mechanism arranged on the culture box in a closed state of the culture box. According to the invention, the culture solution of the culture dish can be replaced when the culture box is closed.

Provided herein are methods of treating or preventing human cytomegalovirus (HCMV) infection comprising modulating interactions between the HCMV gH / gL / UL128-131 A pentamer and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

This invention relates to a hybridoma cell line that secretes a Cy3.5 monoclonal antibody and its application, belonging to the field of immunoassay. The hybridoma cell line of this invention was deposited on November 12, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 46741. The Cy3.5 monoclonal antibody secreted by this cell line exhibits excellent affinity and sensitivity to Cy3.5, with an IC50 of [missing value]. 50 Reaching 10 ng / mL, the IC50 for Cy5.5 50 An immunoassay product based on this hybridoma cell line, with a concentration of up to 50 ng / mL, can be used for the detection of Cy3.5 and its analogues, providing an efficient detection method and means for the residual detection of Cy3.5.

The application discloses a kind of artificial cells for single-cell mass spectrometry and preparation method thereof, wherein artificial cell includes internal water phase, intermediate oil phase and external water phase;Internal water phase includes polyethylene glycol and polyvinyl alcohol aqueous solution, intermediate oil phase includes L-alpha-phosphatidylcholine chloroform and hexane mixture;External water phase includes PVA and F-68 aqueous solution.Compared with natural cell sample, the novel artificial single cell based on microfluidic self-assembly developed in the application has better uniformity, stability and controllability, effectively avoids significant measurement difference between single-cell individual samples, and effectively solves the problem of difficult stable preservation of biological samples.The proposed artificial cell preparation method will largely solve the problem of lack of standard reference material in the field of single-cell mass spectrometry, making the results of single-cell mass spectrometry method more accurate, reliable and mutually recognized.

The application relates to a hybridoma cell strain 1B6A2 secreting an anti-fish T lymphocyte surface membrane protein CD28 monoclonal antibody, the hybridoma cell strain 1B6A2 is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202291, and the preservation date is May 5, 2022. The application provides a powerful tool for simulating a second signal in vitro and exploring a CD28-mediated T cell adaptive immune response mechanism.

Disclosed herein include methods, compositions, and kits suitable for use in preservation (e.g., cryopreservation) of samples. The composition (e.g., cryopreservation reagent) can comprise: one or more cryoprotective agent(s), one or more culture media component(s), one or more carbohydrate(s), and / or one or more amino acid(s). The composition can be capable of maintaining one or more cellular properties and / or cell viability of a plurality of cells in a sample for a period of time under a storage condition. Also provided are methods of sample preservation and sample analysis. The method can comprise contacting a sample with the cryopreservation reagent, thereby generating a shielded sample. The method can comprise exposing the shielded sample to a freezing storage condition, thereby generating a cryopreserved sample.

The invention discloses a water-soluble silk fibroin with a random crimp / Silk I structure as a main structure as well as a preparation method and application of the water-soluble silk fibroin. The silk fibroin product is characterized in that in a protein secondary structure, the total content of random curls and Silk I structures exceeds 85%, and the proportion of Silk I in the whole crystal structure is not lower than 75%; the product can be directly dissolved in water at room temperature to form a stable clarified solution with the concentration not lower than 5%, and is not gelatinized after being stored at 4 DEG C for 90 days. The preparation method comprises the following steps: degumming and cleaning the mulberry silk raw material; the method comprises the following steps: carrying out short-time (less than or equal to 20 minutes) high-temperature dissolution by adopting a multi-element solution dissolution system with a specific ratio, and then carrying out dialysis purification at a low temperature by taking the conductivity (lt, 10 [mu] S / cm) of a dialysis external liquid and the concentration (lt, 50 ppm) of calcium ions as double end-point standards. The directional regulation and control of the silk fibroin structure are realized through the accurate control of the whole process, and the obtained product has excellent water solubility, storage stability and biological safety, and can be widely applied to the fields of drug delivery, 3D biological printing, medical beauty filling, tissue engineering and the like.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present invention discloses a sample cryogenic storage system, including an operation chamber and a storage chamber, where the operation chamber is disposed above the storage chamber and may perform an access operation on a sample stored in the storage chamber; a plurality of storage ports are disposed in an upper end surface of the storage chamber; and a lifting well assembly is disposed in the operation chamber, is movably disposed in the operation chamber, and is movable to the corresponding storage ports to lift a lifting basket in the storage chamber. The present invention has the following beneficial effects: the lifting well assembly lifts the lifting basket in the operation chamber, a shovel plate assembly may push out a plate rack of the lifting basket, a rotary gripping assembly may rotate at 360 degrees to grip the plate rack or the sample, a jacking-up mechanism may jack up a transfer tank and dock the transfer tank with the operation chamber, and the rotary gripping assembly may store the sample or the plate rack from the transfer tank into the lifting basket through the shovel plate assembly and the lifting well assembly, so as to store the lifting basket in the storage chamber, thereby greatly improving the work efficiency.

The application provides a polymerizable human serum albumin bio-ink material and a preparation method and application thereof. The polymerizable human serum albumin is human serum albumin modified by a group containing an unsaturated bond structure. According to the technical scheme of the application, human serum albumin and a compound containing an acrylate structure are used as reaction monomers to perform a reaction, wherein the human serum albumin has good biocompatibility; and the reaction product, the polymerizable human serum albumin, can be used for culturing cells after solidification, and has application prospects of replacing Matrigel used for culturing organoids; in particular, the application can also change the mechanical properties and flexibility of a printed sample by adjusting the concentration of the bio-ink, so as to realize the possibility of oral administration and in-vivo implantation, and expand the application range of the bio-3D printing technology in the biomedical field.

This disclosure relates to a cell sorting apparatus. The cell sorting apparatus includes: a body; a support mechanism, where the support mechanism includes a first support member configured to carry and place a to-be-sorted member for accommodating to-be-sorted cells; an imaging mechanism, configured to obtain image information of the to-be-sorted cells placed in the support mechanism; a display mechanism, configured to display the image information of the to-be-sorted cells obtained by the imaging mechanism; a picking mechanism, configured to suck a cell meeting a preset requirement in the to-be-sorted member; and a control mechanism, configured to control the suck and release of the cell meeting the preset requirement. The cell meeting the preset requirement are sucked by the picking mechanism, so that screening efficiency of the cell sorting apparatus is improved, and high-throughput cell sorting can be implemented.

The subject matter of the present invention is a perfusion fluid in the form of an oil-in-water PFC nanoemulsion, methods of producing this perfusion fluid, and its use in particular for organ perfusion and as a blood substitute preparation.

The application provides a preparation method of a multi-layer sandwich type epoxy group modified magnetic microsphere and application thereof. The multi-layer sandwich type epoxy magnetic microsphere prepared by the preparation method provided in the application can realize efficient and accurate cell sorting through coupling of an antibody, is suitable for cell sorting related scenes such as stem cell separation, tumor cell detection, immune cell treatment (such as CAR-T cell preparation) and pathogenic microorganism enrichment, and provides key material support for cell sorting technology in life science research and clinical diagnosis and treatment.

Provided are anti-CD3 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical composition comprising the same and the uses thereof.